Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2020-08-12 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2020-08-12 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 5, 2020, reporting the resignation of a senior officer (Senior Vice President and Chief Financial Officer) of Caladrius Biosciences, Inc. The key content is about the departure of a principal officer and the appointment transition. There are no financial statements or detailed financial data presented. The primary focus is on management changes, specifically the resignation of a senior executive. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3471 characters, which is short and consistent with a management change announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2020-08-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated July 28, 2020. The key content is the appointment of a new director, Dr. Michael H. Davidson, to the company's Board of Directors, including details about his background, committee assignments, and compensation. The document explicitly states this is an announcement of a board member appointment under Item 5.02, which relates to changes in the company's board or senior management. There is no financial data or report content, only a disclosure of management change. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 5160 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2020-07-28 English
Regulatory Filings 2020
Regulatory Filings
2020-07-27 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-21 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 10, 2020, by Caladrius Biosciences, Inc. It reports the entry into a material definitive agreement related to a private placement of common stock and warrants. The content focuses on the details of the securities purchase agreement, registration rights agreement, and the private placement transaction. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of a capital raising event and related agreements, which fits the category of Capital/Financing Update filings. The length of the document (7030 characters) and the detailed description of the financing transaction support this classification rather than a brief announcement or a regulatory filing fallback.
2020-07-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.